Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Piperoxil (also known as Bibaoning) is a botanical-derived therapeutic preparation, typically a refined extract from the fruit of *Piper longum* (Long Pepper). It is being developed and investigated by institutions such as the Taizhou Hospital of Traditional Chinese Medicine for the treatment of hormone receptor-positive (HR+) breast cancer. The drug is administered in capsule form and is primarily studied in combination with endocrine therapy to overcome or reverse endocrine resistance in patients who have progressed on standard hormonal treatments. The pharmacological activity of Piperoxil is attributed to its alkaloid components, which are thought to modulate signaling pathways involved in tumor cell proliferation and drug resistance, although its precise molecular targets in the context of breast cancer are still being characterized in clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on piperoxil.